We would like to get input from the LOINC community regarding the FLT3-ITD test mapping granularity.
We have a local test reporting FLT3-ITD mutation detected and another local test reporting the FLT3-ITD mutation detected in exon 14 and 15 (1). We know that FLT3-ITD mutation can be detected in exon 11& 12 (2) from publications. Should we create 2 local LOINC codes* for exon specific and non-specific tests?
- LOINC has no office code for FLT3-ITD test at this moment yet.
(1) Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
(2) Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay